Chemotherapy in carcinomas of unknown primary site: A high-dose intensity policy
Open Access
- 1 May 1999
- journal article
- Published by Elsevier in Annals of Oncology
- Vol. 10 (5) , 569-576
- https://doi.org/10.1023/a:1026478009050
Abstract
No abstract availableKeywords
This publication has 10 references indexed in Scilit:
- Mitomycin C, Epirubicin and Cisplatin versus Mitomycin C Alone as Therapy for Carcinoma of Unknown Primary OriginOncology, 1998
- Four-step high-dose sequential chemotherapy with hematopoietic progenitor-cell support as induction treatment for patients with solid tumorsAnnals of Oncology, 1997
- Carcinoma of unknown primary site: treatment with 1-hour paclitaxel, carboplatin, and extended-schedule etoposide.Journal of Clinical Oncology, 1997
- Cancer of unknown primary siteCancer, 1995
- Treatment of Patients with Cancer of an Unknown Primary SiteNew England Journal of Medicine, 1993
- Cisplatin-based combination chemotherapy in the treatment of poorly differentiated carcinoma and poorly differentiated adenocarcinoma of unknown primary site: results of a 12-year experience.Journal of Clinical Oncology, 1992
- Metastatic adenocarcinoma of unknown primary site. A randomized study of two combination chemotherapy regimensEuropean Journal of Cancer and Clinical Oncology, 1987
- Lack of Value for Cisplatin Added to Mitomycin-Doxorubicin Combination Chemotherapy for Carcinoma of Unknown Primary Site A Randomized TrialAmerican Journal of Clinical Oncology, 1987
- Reporting results of cancer treatmentCancer, 1981
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958